MX2011012839A - Antagonistas policiclicos de receptores de acido lisofosfatidico. - Google Patents

Antagonistas policiclicos de receptores de acido lisofosfatidico.

Info

Publication number
MX2011012839A
MX2011012839A MX2011012839A MX2011012839A MX2011012839A MX 2011012839 A MX2011012839 A MX 2011012839A MX 2011012839 A MX2011012839 A MX 2011012839A MX 2011012839 A MX2011012839 A MX 2011012839A MX 2011012839 A MX2011012839 A MX 2011012839A
Authority
MX
Mexico
Prior art keywords
antagonists
lysophosphatidic acid
acid receptors
polycyclic
compounds
Prior art date
Application number
MX2011012839A
Other languages
English (en)
Inventor
John Howard Hutchinson
Jeffrey Roger Roppe
Jeannie M Arruda
Thomas Jon Seiders
Bowei Wang
Timothy Parr
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of MX2011012839A publication Critical patent/MX2011012839A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

En la presente se describen compuestos que son antagonistas de receptores lifofosfatídicos. También se describen composiciones farmacéuticas y medicamentos que incluyen los compuestos descritos en la presente, así como métodos para utilizar tales antagonistas, solos o en combinación con otros compuestos, para tratar afecciones o enfermedades mediadas por LPA o dependientes de LPA.
MX2011012839A 2009-06-03 2010-06-03 Antagonistas policiclicos de receptores de acido lisofosfatidico. MX2011012839A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18378509P 2009-06-03 2009-06-03
PCT/US2010/037309 WO2010141761A2 (en) 2009-06-03 2010-06-03 Polycyclic antagonists of lysophosphatidic acid receptors

Publications (1)

Publication Number Publication Date
MX2011012839A true MX2011012839A (es) 2012-04-02

Family

ID=42471045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012839A MX2011012839A (es) 2009-06-03 2010-06-03 Antagonistas policiclicos de receptores de acido lisofosfatidico.

Country Status (29)

Country Link
US (2) US8058300B2 (es)
EP (1) EP2438048B1 (es)
JP (1) JP5599457B2 (es)
KR (2) KR101774722B1 (es)
CN (2) CN102459204B (es)
AU (2) AU2010256501B2 (es)
BR (1) BRPI1014582A2 (es)
CA (1) CA2764445C (es)
CL (1) CL2011003072A1 (es)
CO (1) CO6480918A2 (es)
DK (1) DK2438048T3 (es)
EA (1) EA020139B1 (es)
ES (1) ES2445714T3 (es)
GB (1) GB2470833B (es)
HK (1) HK1163085A1 (es)
HR (1) HRP20140036T1 (es)
IL (2) IL216220A (es)
MX (1) MX2011012839A (es)
MY (1) MY163055A (es)
NZ (1) NZ596826A (es)
PE (1) PE20120936A1 (es)
PL (1) PL2438048T3 (es)
PT (1) PT2438048E (es)
SG (1) SG176112A1 (es)
SI (1) SI2438048T1 (es)
SM (1) SMT201400031B (es)
TW (1) TWI405757B (es)
WO (2) WO2010141768A2 (es)
ZA (1) ZA201108421B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
TW201117809A (en) * 2009-09-25 2011-06-01 Astellas Pharma Inc Substituted amide compounds
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
BR112012013908B1 (pt) * 2009-12-11 2020-11-03 Pirelli Tyre S.P.A pneu para uma roda de um veículo de carga pesada
DK2648726T3 (da) * 2010-12-07 2018-07-16 Amira Pharmaceuticals Inc Polycyklisk lpa1-antagonist og anvendelser deraf
JP2014513077A (ja) 2011-04-05 2014-05-29 アミラ ファーマシューティカルス，インコーポレーテッド 線維症、疼痛、癌、ならびに呼吸器、アレルギー性、神経系または心血管疾患の治療に有用な３−または５−ビフェニル−４−イルイソキサゾールに基づく化合物
WO2013025733A1 (en) * 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2013070879A1 (en) * 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
EP2783016A1 (en) 2011-11-22 2014-10-01 Intermune, Inc. Methods of diagnosing and treating idiopathic pulmonary fibrosis
IN2014DN09348A (es) * 2012-06-20 2015-07-17 Hoffmann La Roche
IN2014DN09347A (es) * 2012-06-20 2015-07-17 Hoffmann La Roche
US20150306099A1 (en) * 2012-11-27 2015-10-29 Glaxosmithkline Llc Combination
WO2014104372A1 (ja) 2012-12-28 2014-07-03 宇部興産株式会社 ハロゲン置換へテロ環化合物
TW201437200A (zh) * 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
WO2015066456A1 (en) 2013-10-31 2015-05-07 Bristol-Myers Squibb Company Radioligands for imaging the lpa-1 receptor
RU2689315C2 (ru) 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
TWI770157B (zh) * 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
EA201992386A1 (ru) * 2017-04-10 2020-03-27 Байер Акциенгезельшафт Замещенные n-арилэтил-2-арилхинолин-4-карбоксамиды и их применение
CA3106692A1 (en) * 2017-07-19 2019-01-24 Aazeintx Inc. Method to abate acute airway hypersensitivity and asthma attacks
EP3710444B1 (en) 2017-11-14 2023-04-12 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11498904B2 (en) 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
KR20200100724A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산
EP3807254A4 (en) * 2018-06-18 2022-03-23 Epigen Biosciences, Inc. HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE
JP7427658B2 (ja) 2018-09-18 2024-02-05 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロペンチル酸
KR20220024550A (ko) 2019-06-18 2022-03-03 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로부틸 카르복실산
KR20220024549A (ko) * 2019-06-18 2022-03-03 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 카르복실산
CN114599648A (zh) 2019-06-18 2022-06-07 百时美施贵宝公司 作为lpa拮抗剂的***羧酸
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
JP2023504415A (ja) 2019-12-04 2023-02-03 イドーシア ファーマシューティカルズ リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤
KR102393079B1 (ko) 2020-02-28 2022-04-29 한국화학연구원 가축 호흡기 질환의 예방 또는 치료용 조성물
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CN115867556A (zh) 2020-06-03 2023-03-28 吉利德科学公司 Lpa受体拮抗剂及其用途
CN114456157A (zh) * 2020-11-10 2022-05-10 武汉人福创新药物研发中心有限公司 氮取代氨基碳酸酯噻吩类化合物及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
AU6645998A (en) 1996-12-23 1998-07-17 Du Pont Pharmaceuticals Company Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
JP3237608B2 (ja) 1997-04-21 2001-12-10 住友製薬株式会社 イソキサゾール誘導体
DE60003025T2 (de) 1999-04-02 2004-03-18 Bristol-Myers Squibb Pharma Co. Arylsulfonyle als faktor xa inhibitoren
PT1258484E (pt) * 2000-02-18 2009-04-03 Kyowa Hakko Kirin Co Ltd Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
WO2002062389A1 (fr) * 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2004526803A (ja) * 2001-04-25 2004-09-02 バイオサイナーゲン、インコーポレーテッド リゾフォスファチジン酸を含む薬剤学的組成物（ａｐｈａｒｍａｃｅｕｔｉｃａｌｃｏｍｐｏｓｉｔｉｏｎｃｏｍｐｒｉｓｉｎｇｌｙｓｏｐｈｏｓｐｈａｔｉｄｉｃａｃｉｄ）
EP1415667B1 (en) * 2001-07-17 2008-09-03 Ono Pharmaceutical Co., Ltd. Pancreatic juice secretion regulators comprising lpa receptor controller
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
EP1466602A4 (en) * 2001-12-25 2006-03-01 Ajinomoto Kk ORGAN FIBROSIS INHIBITORS
US20050101518A1 (en) * 2002-01-18 2005-05-12 David Solow-Cordero Methods of treating conditions associated with an EDG-2 receptor
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20040014662A1 (en) * 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
CA2484233A1 (en) * 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
EP1533294A4 (en) * 2002-05-28 2007-07-04 Ono Pharmaceutical Co BETA-ALANINE DERIVATIVE AND USE THEREOF
JPWO2004002530A1 (ja) * 2002-06-26 2005-10-27 小野薬品工業株式会社 慢性疾患治療剤
WO2004031118A1 (ja) 2002-10-03 2004-04-15 Ono Pharmaceutical Co., Ltd. Ｌｐａ受容体拮抗剤
WO2004046332A2 (en) * 2002-11-19 2004-06-03 Amgen Inc. Amplified genes involved in cancer
US20040167132A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associted with an Edg-2 receptor
US20040192739A1 (en) * 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
US20050065194A1 (en) * 2003-01-16 2005-03-24 Geetha Shankar Methods of treating conditions associated with an Edg-2 receptor
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
CA2521189A1 (en) 2003-04-11 2004-10-28 Gabor Tigyi Lysophosphatidic acid analogs and inhibition of neointima formation
US7115642B2 (en) * 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
JP4692281B2 (ja) * 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
CA2540809C (en) 2003-10-09 2013-09-24 University Of Tennessee Research Foundation Lpa receptor agonists and antagonists and methods of use
JP4766384B2 (ja) 2003-12-19 2011-09-07 小野薬品工業株式会社 リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途
DE10360369A1 (de) * 2003-12-22 2005-07-14 Bayer Cropscience Ag Amide
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP2006096712A (ja) 2004-09-30 2006-04-13 Senju Pharmaceut Co Ltd Ｌｐａ受容体拮抗剤を含有する角膜知覚改善剤
AU2006256968A1 (en) 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or I soxazoles and their use as SIP receptor ligands
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
JP2008546651A (ja) * 2005-06-14 2008-12-25 メルク フロスト カナダ リミテツド モノアミンオキシダーゼａ及びｂの可逆的阻害剤
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
AU2006283175A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
EP2013176A2 (en) * 2006-02-27 2009-01-14 Sterix Limited Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
JP2009545531A (ja) 2006-07-24 2009-12-24 ユニバーシティ オブ バージニア パテント ファンデーション ホスホン酸ビニルリゾホスファチジン酸受容体拮抗薬
US20080051372A1 (en) * 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
WO2008024979A2 (en) 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
AU2007334436A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
US20100143381A1 (en) 2007-03-12 2010-06-10 Andrew Tager Lysophosphatidic acid receptor targeting for lung disease
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
CN105461589A (zh) 2008-05-05 2016-04-06 赛诺菲-安万特 酰基氨基取代的稠合环戊烷羧酸衍生物及它们作为药物的用途
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
WO2011159632A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions

Also Published As

Publication number Publication date
WO2010141768A2 (en) 2010-12-09
JP5599457B2 (ja) 2014-10-01
WO2010141761A2 (en) 2010-12-09
CN102459204B (zh) 2015-08-12
AU2010256501A1 (en) 2011-12-22
KR20160068984A (ko) 2016-06-15
CA2764445A1 (en) 2010-12-09
HK1163085A1 (en) 2012-09-07
DK2438048T3 (en) 2014-03-17
AU2016202676B2 (en) 2018-02-22
EP2438048A4 (en) 2012-11-07
ZA201108421B (en) 2013-04-24
WO2010141761A3 (en) 2011-04-21
GB2470833A8 (en) 2011-03-30
EP2438048A2 (en) 2012-04-11
IL240749B (en) 2018-07-31
GB2470833A (en) 2010-12-08
KR101628706B1 (ko) 2016-06-09
NZ596826A (en) 2014-03-28
SG176112A1 (en) 2011-12-29
IL240749A0 (en) 2015-10-29
IL216220A (en) 2015-09-24
KR101774722B1 (ko) 2017-09-04
TWI405757B (zh) 2013-08-21
US8273780B2 (en) 2012-09-25
PT2438048E (pt) 2014-02-26
EA201101709A1 (ru) 2012-06-29
CO6480918A2 (es) 2012-07-16
CN102459204A (zh) 2012-05-16
PL2438048T3 (pl) 2014-05-30
GB2470833B (en) 2011-06-01
SI2438048T1 (sl) 2014-04-30
AU2010256501B2 (en) 2016-04-21
US20100311799A1 (en) 2010-12-09
GB201009231D0 (en) 2010-07-21
CL2011003072A1 (es) 2012-04-27
WO2010141768A3 (en) 2011-03-31
US20120015991A1 (en) 2012-01-19
EA020139B1 (ru) 2014-08-29
TW201103896A (en) 2011-02-01
JP2012528884A (ja) 2012-11-15
ES2445714T3 (es) 2014-03-04
AU2016202676A1 (en) 2016-05-26
SMT201400031B (it) 2014-05-07
EP2438048B1 (en) 2013-12-18
HRP20140036T1 (hr) 2014-02-14
BRPI1014582A2 (pt) 2016-04-26
MY163055A (en) 2017-08-15
IL216220A0 (en) 2012-01-31
KR20120026593A (ko) 2012-03-19
CA2764445C (en) 2018-01-02
US8058300B2 (en) 2011-11-15
CN105061346A (zh) 2015-11-18
PE20120936A1 (es) 2012-08-01

Similar Documents

Publication Publication Date Title
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
IN2012DN02735A (es)
IN2012DN00754A (es)
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
PH12015501737A1 (en) Androgen receptor modulators and uses thereof
WO2010068775A3 (en) Alkyne antagonists of lysophosphatidic acid receptors
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2011156518A3 (en) Estrogen receptor modulators and uses thereof
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
WO2014066799A3 (en) Modulators of resistant androgen receptor

Legal Events

Date Code Title Description
FG Grant or registration